Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (20)

2024

  1. Oscillatory vs. non-oscillatory subthalamic beta activity in Parkinson's disease

    Journal of Physiology, Vol. 602, Núm. 2, pp. 373-395

2021

  1. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease

    European Journal of Pharmacology, Vol. 895

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. NT3/TrkC Pathway Modulates the Expression of UCP-1 and Adipocyte Size in Human and Rodent Adipose Tissue

    Frontiers in Endocrinology, Vol. 12

2020

  1. The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas

    Science Translational Medicine, Vol. 12, Núm. 527

2018

  1. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor

    Journal of Neuroinflammation, Vol. 15, Núm. 1

2017

  1. Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)

    Pharmacological Research

  2. Targeting of the Subthalamic Nucleus for Deep Brain Stimulation: A Survey Among Parkinson Disease Specialists

    World Neurosurgery, Vol. 99, pp. 41-46

2016

  1. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile

    Pharmacological Research, Vol. 110, pp. 205-215

  2. Hemorragia subaracnoidea por rotura de aneurisma especular intracraneal. A propósito de un caso y revisión de la literatura

    Neurologia

  3. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2receptor ligands with antagonist/inverse agonist properties

    European Journal of Medicinal Chemistry, Vol. 112, pp. 66-80

2015

  1. Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists

    European Journal of Medicinal Chemistry, Vol. 101, pp. 651-667

2014

  1. 0468. Cerebral effects of lateral trendelenburg vs semirecumbent position in an experimental model of ventilator-associated pneumonia

    Intensive Care Medicine Experimental

2013

  1. Neuroprotective properties of standardized extracts of hypericum perforatum on rotenone model of parkinson's disease

    CNS and Neurological Disorders - Drug Targets, Vol. 12, Núm. 5, pp. 665-679

2011

  1. A combined preclinical therapy of cannabinoids and temozolomide against glioma

    Molecular Cancer Therapeutics, Vol. 10, Núm. 1, pp. 90-103

  2. Stimulation of ALK by the growth factor midkine renders glioma cells resistant to autophagy-mediated cell death

    Autophagy, Vol. 7, Núm. 9, pp. 1071-1073

  3. Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action

    Cell Death and Differentiation, Vol. 18, Núm. 6, pp. 959-973

  4. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ 9-THCV in animal models of Parkinson's disease

    British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1495-1506

2010

  1. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice

    PLoS ONE, Vol. 5, Núm. 7, pp. 1-15

2007

  1. Cannabinoids and neuroprotection in Basal ganglia disorders

    Molecular Neurobiology, Vol. 36, Núm. 1, pp. 82-91